Botox-Maker Pays $600 Million to Resolve DOJ Investigation
September 1, 2010
Allergan will pay $600 million to settle a years-long federal investigation into how it marketed its top-selling drug Botox, reports the Associated Press. The company says it will plead guilty to one misdemeanor charge of "misbranding," in which the company''s marketing led physicians to use Botox for unapproved uses. Those uses included the treatment of headache, pain, spasticity and cerebral palsy. The company will pay $375 million in connection with the plea. In addition, the company will pay $225 million in civil fines related to the investigation, though the company denies liability. The Department of Justice began investigating Allergan''s marketing in 2000.